AI-Powered Prognostic Assay for ER+/HER2- Early Breast Cancer
Early-stage, Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
ValidatedActive
Key Facts
Indication
Early-stage, Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
Phase
Validated
Status
Active
Company
About Spotlight Medical
Spotlight Medical is a Paris-based, AI-powered diagnostics company focused on precision oncology. Leveraging decades of patient data and multimodal biological information, it builds prognostic tests to identify which cancer patients are at high or low risk of relapse, thereby guiding more tailored treatment decisions. The company has validated its first assay in breast cancer, secured seed funding, and is building a team to advance its platform. Its core value proposition is reducing overtreatment and side effects while improving cure rates through data-driven clinical tools.
View full company profile